Antipsychotic response in first-episode schizophrenia: Efficacy of high doses and switching

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1017-1022

  Agid, Ofer ^a,b   Schulze, Laura ^a,c   Arenovich, Tamara ^a   Sajeev, Gautam ^a   McDonald, Krysta ^a   Foussias, George ^a,b,c   Fervaha, Gagan ^a,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic dosing; Antipsychotic switching; Antipsychotic trials; First episode schizophrenia; Treatment algorithm

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; FIRST EPISODE SCHIZOPHRENIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC DOSING; ANTIPSYCHOTIC SWITCHING; ANTIPSYCHOTIC TRIALS; FIRST-EPISODE SCHIZOPHRENIA; TREATMENT ALGORITHM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884209346     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.04.010     Document Type: Article

References (45)

1. Agid O, Arenovich T., Sajeev G., Zipursky R.B., Kapur S., Foussias G., Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J. Clin. Psychiatry 2011, 72:1439-1444.
2. Agid O., Remington G., Kapur S., Arenovich T., Zipursky R.B. Early use of clozapine for poorly responding first-episode psychosis. J. Clin. Psychopharmacol. 2007, 27:369-373.
3. Altamura A.C., Buoli M., Mauri M.C. Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study. J. Clin. Psychopharmacol. 2011, 31:661-663.
4. American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 1-140.
5. Attard A., Taylor D.M. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?. CNS Drugs 2012, 26:491-508.
6. Barbui C., Biancosino B., Esposito E., Marmai L., Dona S., Grassi L. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int. Clin. Psychopharmacol. 2007, 22:221-225.
7. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., Kahn R.S. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 2009, 115:97-103.
8. Botts S., Littrell R., de Leon J. Variables associated with high olanzapine dosing in a state hospital. J. Clin. Psychiatry 2004, 65:1138-1143.
9. Buckley P.F., Correll C.U. Strategies for dosing and switching antipsychotics for optimal clinical management. J. Clin. Psychiatry 2008, 69(Suppl 1):4-17.
10. Canadian Psychiatric Association Clinical practice guidelines: treatment of schizophrenia. Can. J. Psychiatry 2005, 50:1S-56S.
11. Chang W.C., Tang J.Y., Hui C.L., Lam M.M., Wong G.H., Chan S.K., Chiu C.P., Chung D.W., Law C.W., Tso S., Chan K., Hung S.F., Chen E.Y. Duration of untreated psychosis: relationship with baseline characteristics and three-year outcome in first-episode psychosis. Psychiatry Res. 2012, 198:360-365.
12. Crespo-Facorro B., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry 2006, 67:1511-1521.
13. Derks E.M., Fleischhacker W.W., Boter H., Peuskens J., Kahn R.S. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?. J. Clin. Psychopharmacol 2010, 30:176-180.
14. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry 2006, 67:1707-1712.
15. Emsley R., Rabinowitz J., Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 2006, 163:743-745.
16. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., Lieberman J.A. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 2006, 163:2090-2095.
17. Guy W. Assessment Manual for Psychopharmacology 1976, National Institute of Mental Health, Rockville, MD.
18. Hanssens L., De Hert M., Wampers M., Reginster J.Y., Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin. Pract. Epidemiol. Ment. Health 2006, 2:11.
19. Haro J.M., Novick D., Suarez D., Alonso J., Lepine J.P., Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J. Clin. Psychopharmacol. 2006, 26:571-578.
20. Kilian R., Steinert T., Schepp W., Weiser P., Jaeger S., Pfiffner C., Frasch K., Eschweiler G.W., Messer T., Croissant D., Becker T., Langle G. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:589-598.
21. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol. Bull. 1993, 29:309-314.
22. Kinon B.J., Volavka J., Stauffer V., Edwards S.E., Liu-Seifert H., Chen L., Adams D.H., Lindenmayer J.P., McEvoy J.P., Buckley P.F., Lieberman J.A., Meltzer H.Y., Wilson D.R., Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 2008, 28:392-400.
23. Leucht S., Heres S., Kissling W., Davis J.M. Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:269-284.
24. Lieberman J., Jody D., Geisler S., Vital-Herne J., Alvir J.M., Walsleben J., Woerner M.G. Treatment outcome of first episode schizophrenia. Psychopharmacol. Bull. 1989, 25:92-96.
25. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 1996, 57(Suppl 9):5-9.
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
27. Longenecker J., Genderson J., Dickinson D., Malley J., Elvevag B., Weinberger D.R., Gold J. Where have all the women gone?: Participant gender in epidemiological and non-epidemiological research of schizophrenia. Schizophr. Res. 2010, 119:240-245.
28. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991, 48:739-745.
29. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
30. Merlo M.C., Hofer H., Gekle W., Berger G., Ventura J., Panhuber I., Latour G., Marder S.R. Risperidone, 2mg/day vs. 4mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J. Clin. Psychiatry 2002, 63:885-891.
31. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Essock S.M., Finnerty M., Marder S.R., Miller D., McEvoy J.P., Robinson D.G., Schooler N.R., Shon S.P., Stroup T.S., Miller A.L. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J. Clin. Psychiatry 2007, 68:1751-1762.
32. National Institute of Clinical Excellence (NICE) NICE Clinical Guideline 82-Schizophrenia 2009, NICE, London.
33. Novick D., Haro J.M., Suarez D., Lambert M., Lepine J.P., Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl) 2007, 191:1015-1022.
34. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
35. Perkins D., Lieberman J., Gu H., Tohen M., McEvoy J., Green A., Zipursky R., Strakowski S., Sharma T., Kahn R., Gur R., Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br. J. Psychiatry 2004, 185:18-24.
36. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162:1785-1804.
37. Rosenheck R.A., Davis S., Covell N., Essock S, Swartz M., Stroup S., McEvoy J., Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr. Res. 2009, 107:22-29.
38. Schennach-Wolff R., Seemuller F.H., Mayr A., Maier W., Klingberg S., Heuser I., Klosterkotter J., Gastpar M., Hafner H., Sauer H., Schneider F., Gaebel W., Jager M., Moller H.J., Riedel M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br. J. Psychiatry 2010, 196:460-496.
39. Sernyak M.J., Rosenheck R. Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications. Adm. Policy Ment. Health 2007, 34:540-547.
40. Simonsen E., Friis S., Haahr U., Johannessen J.O., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Vaglum P., McGlashan T. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr. Scand. 2007, 116:54-61.
41. Simonsen E., Friis S., Opjordsmoen S., Mortensen E.L., Haahr U., Melle I., Joa I., Johannessen J.O., Larsen T.K., Rossberg J.I., Rund B.R., Vaglum P., McGlashan T.H. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr. Scand. 2010, 122:375-383.
42. Stauffer V.L., Case M., Kinon B.J., Conley R., Ascher-Svanum H., Kollack-Walker S., Kane J., McEvoy J., Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011, 187:42-48.
43. Takahashi H., Kamata M., Yoshida K., Ishigooka J., Higuchi H. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J. Clin. Psychiatry 2006, 67:1577-1582.
44. Takahashi H., Yoshida K., Ishigooka J., Higuchi H. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1067-1072.
45. Whitty P., Clarke M., McTigue O., Browne S., Kamali M., Kinsella A., Larkin C., O'Callaghan E. Predictors of outcome in first-episode schizophrenia over the first 4 years of illness. Psychol. Med. 2008, 38:1141-1146.